Trehalose

DB12310InvestigationalSmall molecule

Cabaletta has been used in trials studying the treatment of Oculopharyngeal Muscular Dystrophy.

Mechanism: Pharmacologically active on Transcription factor EB
Curator reviewed
Formula / weight: C₁₂H₂₂O₁₁ · 342.2965 g/mol (avg)
Also known as: Cabaletta
Code names: SLS-005

Resolves to

Compound

Clinical / RWD

Structure

InChIKeyHDTRYLNUVZCQOY-LIZSDCNHSA-NSMILESOC[C@H]1O[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O

Targets

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

29Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Trehalose, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.